Clinical Trials in San Diego

Showing 10021-10040 of 12,589 trials

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

NCT02291809

The primary objective is to compare \& evaluate between the treatment groups the changes in decline/reduction of HIV viral load \& increase changes in WBC white blood cell counts in the adult Remune dose vs the low dose Remune placebo groups. Additional objectives include changes in CD4+ \& CD8+ T cell counts along with increased HIV immunity.

HIV/AIDS

Immune Response BioPharma, Inc.26 participantsStarted Nov 2017

San Diego, California, United States

COMPLETEDPhase 4< 1 mile

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

NCT00077636

This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

Hepatitis C, Chronic

Hoffmann-La Roche1,469 participantsStarted Dec 2003

Birmingham, Alabama, United States • Mobile, Alabama, United States • Anchorage, Alaska, United States +129 more locations

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

Find Trials by Condition in San Diego

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

Blood and Marrow Transplant Clinical Research Network

User Study of an Investigational Blood Glucose Monitoring System

Performance of a New Glucose Meter System

GORE Flow Reversal System and GORE Embolic Filter Extension Study

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine

Intradiscal rhGDF-5 Phase I/II Clinical Trial

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Relapse Prevention Study in Newly Abstinent Smokers

Multi-site Decision Impact Study for Decipher

Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents

Atacicept in Subjects With Optic Neuritis

Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)